

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A
(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2015

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other Jurisdiction of Incorporation)

000-55158
(Commission File Number)

20-5978559
(IRS Employer Identification No.)

19805 North Creek Parkway
Bothell, WA
(Address of principal executive offices)

98011
(Zip Code)

Registrant's telephone number, including area code: (425) 398-7178

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Explanatory Note

On July 2, 2015, Cocrystal Pharma, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) related to the Company’s 2015 Annual Meeting of Shareholders held on June 29, 2015. This Current Report on Form 8-K/A is being filed solely to update the disclosures made under Item 5.07 of the Original Report regarding the frequency of future non-binding, advisory votes on executive compensation.

Item 5.07 Submission of Matters to a Vote of Security Holders.

As previously reported, on June 29, 2015, the Company held its Annual Meeting of Shareholders at which the Company’s shareholders voted on a number of proposals, including an advisory vote on the frequency of future shareholder advisory votes on executive compensation. The Board of Directors, taking into consideration the fact that 98% of the votes cast by shareholders were in favor of a three-year frequency, has determined that the Company will hold future shareholder advisory votes on executive compensation every three years.

Date: August 3, 2015

Cocrystal Pharma, Inc.

By: /s/ Walt A. Linscott

Name: Walt A. Linscott

Title: General Counsel and Secretary